BRAIN Group's Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform
- Mode of action suited for applications in oncology
- Significantly increased addressable market potential
Lukas Linnig, Co-Founder and Co-CEO Akribion Genomics (in founding), comments: “This opens up a significantly increased addressable market potential for our proprietary genome-editing platform technology. The next logical step will be to form strong partnerships with companies in the field of cell delivery systems which are going to be critical to address various applications in oncology. We are currently building up our partner network to further enlarge the areas of application.” Adriaan Moelker, CEO BRAIN Biotech AG adds: “The increased focus of Akribion Genomics on therapeutic applications further supports our intention to spin-out our proprietary genome-editing technology (GeditingTM) into the separate legal entity Akribion Genomics. This will allow a better development of applications which go beyond the current core activities of the BRAIN-Group and to attract additional funding for accelerated growth. We will continue to employ the GeditingTM platform for the benefit of all of our customers also in industrial applications.”
On April 4, 2022, BRAIN Biotech had announced demonstrating successfully genome-editing of mammalian cells with its proprietary CRISPR-Cas genome editing nucleases. These BRAIN-developed genome-editing nucleases (G-dasesTM) are already today successfully employed in customer projects within the company´s BioScience division and are utilized for the optimization of highly efficient microbial producer strains which power the biological production in so-called microbial cell factories. The G-dasesTM are currently being advanced for applications in agriculture, therapeutics, marine applications and industrial producer strains.
BRAIN Biotech AG ("BRAIN") is a leading European specialist in industrial biotechnology with a focus on nutrition, health and environment. As a technology and solution provider, the company supports the biologization of industry with biobased products and processes. From contract research and development with industrial partners to the development of own disruptive incubator projects and customized enzyme products: BRAIN's broad, innovative biotech know-how and its agile teams are the key to its success.
The German BRAIN Biotech AG is the parent company of the international BRAIN Group, which distributes B2B specialty products, including enzymes and bioactive natural products. The BRAIN Group has its own fermentation or production facilities in continental Europe, the UK and the USA, which, together with the associated biotechnological production know-how, complete the value chain within the Group.
As a participant in the United Nations Global Compact, BRAIN Biotech AG is committed to aligning its strategies and activities with universal principles on human rights, labor, the environment and anti-corruption, and to actively promote common social goals. BRAIN Biotech´s products and services directly target at least five of the UN SDGs.
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.